Association between Helicobacter pylori infection and duodenal ulcer
- Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF
Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF
- Professor of Medicine
- University of California, San Diego
The majority of patients with duodenal ulcer (DU) are infected with Helicobacter pylori (H. pylori). However, in multicenter trials, H. pylori was absent in almost 30 percent of patients with an endoscopically documented duodenal ulcer . Studies that have investigated these patients found that they have generally had a shorter duration of symptoms and that many had regularly used nonsteroidal anti-inflammatory drugs (NSAIDs) [2-4]. Such patients have a significantly worse outcome, especially if treated empirically for H. pylori infection. Thus, H. pylori status should be determined in all ulcer patients before initiating treatment . High acid output may be a cause of recurrent DU in patients in whom H. pylori has been eradicated . A variety of other causes are responsible for the remaining cases. (See "Unusual causes of peptic ulcer disease".)
The link between H. pylori and DU will be reviewed here. The pathophysiology of H. pylori infection as it relates to gastrointestinal disease in general is discussed separately. (See "Pathophysiology of and immune response to Helicobacter pylori infection".)
EVIDENCE LINKING HELICOBACTER PYLORI TO DUODENAL ULCERS
There are several lines of evidence that implicate H. pylori as a major etiologic factor in duodenal ulcers (DU):
●H. pylori is present in most patients who have a DU that is not related to NSAID use
●H. pylori infection is detectable before the occurrence of DU and appears to be a risk factor for the disorderTo continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94:1834.
- Tytgat G, Langenberg W, Rauws E, Rietra P. Campylobacter-like organism (CLO) in the human stomach. Gastroenterology 1985; 88:1620.
- McColl KE, el-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34:762.
- Bytzer P, Teglbjaerg PS, Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96:1409.
- Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997; 11:331.
- Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985; 142:439.
- Borody TJ, George LL, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991; 86:1154.
- Dwyer B, Sun NX, Kaldor J, et al. Antibody response to Campylobacter pylori in an ethnic group lacking peptic ulceration. Scand J Infect Dis 1988; 20:63.
- Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010; 105:2570.
- Sipponen P, Varis K, Fräki O, et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol 1990; 25:966.
- Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120:977.
- Cullen D, Collins B, Christiansen K. Long term risk of peptic ulcer disease in people with H pylori infection - A community based study. Gastroenterology 1993; 104 (Suppl):A60.
- Leoci C, Ierardi E, Chiloiro M, et al. Incidence and risk factors of duodenal ulcer. A retrospective cohort study. J Clin Gastroenterol 1995; 20:104.
- Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.
- Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.
- el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681.
- el-Omar E, Penman I, Dorrian CA, et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993; 34:1060.
- Peterson WL, Barnett CC, Evans DJ Jr, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88:2038.
- Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med 1995; 27:569.
- McColl KE. Helicobacter pylori: clinical aspects. J Infect 1997; 34:7.
- Harris AW, Gummett PA, Misiewicz JJ, Baron JH. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 1996; 38:663.
- Moss S, Ayesu K, Calam J. Gastrin and gastric acid output one year after eradication of Helicobacter pylori in duodenal ulcer patients. Regul Pept 1991; 35:251.
- Gillen D, el-Omar EM, Wirz AA, et al. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998; 114:50.
- Moss SF, Legon S, Bishop AE, et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340:930.
- Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993; 34:888.
- Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 1987; 40:841.
- Hogan DL, Rapier RC, Dreilinger A, et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology 1996; 110:705.
- Hamlet A, Thoreson AC, Nilsson O, et al. Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology 1999; 116:259.
- Peura DA. Ulcerogenesis: integrating the roles of Helicobacter pylori and acid secretion in duodenal ulcer. Am J Gastroenterol 1997; 92:8S.
- Konturek PC, Ernst H, Konturek SJ, et al. Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori. Gut 1997; 40:463.
- Isenberg J, McQuaid K, Laine L, Walsh J. Acid-Peptic Disorders. In: Textbook of Gastroenterology, 2nd ed, Yamada T (Ed), JP Lippincott, Philadelphia 1995. p.1347.
- Blaser MJ. Role of vacA and the cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996; 10 Suppl 1:73.
- Weel JF, van der Hulst RW, Gerrits Y, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996; 173:1171.
- Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005; 128:833.
- Yamaoka Y. Roles of the plasticity regions of Helicobacter pylori in gastroduodenal pathogenesis. J Med Microbiol 2008; 57:545.
- Azuma T, Konishi J, Ito Y, et al. Genetic differences between duodenal ulcer patients who were positive or negative for Helicobacter pylori. J Clin Gastroenterol 1995; 21 Suppl 1:S151.
- Graham DY. Helicobacter pylori and perturbations in acid secretion: the end of the beginning. Gastroenterology 1996; 110:1647.
- Strömberg E, Edebo A, Lundin BS, et al. Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. Clin Exp Immunol 2005; 140:117.
- Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41:459.
- Martin DF, Montgomery E, Dobek AS, et al. Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989; 84:1268.
- Hawkey CJ. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 2000; 46:310.
- Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.
- Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30:791.
- McColl KE. How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol 2009; 104:190.
- Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.
- Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359:9.
- Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352:1016.
- EVIDENCE LINKING HELICOBACTER PYLORI TO DUODENAL ULCERS
- Incidence of H. pylori in patients with duodenal ulcer
- H. pylori occurs before manifestations of the disease
- Eradication of H. pylori reduces disease recurrence
- PATHOGENESIS OF ULCER FORMATION
- Increased gastric acid secretion
- Gastric metaplasia
- Immune response
- Mucosal defense factors
- Other contributing factors
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS